Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124211 | 0.95 | OPRM1 (0.34) | DRD2OPRM1KDM4EALDH1A1TDP1 | |
| SCHEMBL3129167 | 0.78 | ALDH1A1 (0.36) | KDM4EALDH1A1TDP1 | |
| SCHEMBL14833411 | 0.75 | DRD2 (0.38) | DRD2OPRM1OPRD1OPRK1 | |
| SCHEMBL17810250 | 0.68 | GRIN1 (0.46) | OPRM1OPRD1OPRK1 | |
| SCHEMBL7452158 | 0.68 | CHRNB4 (0.35) | DRD2 | |
| SCHEMBL27677030 | 0.67 | LTA4H (0.39) | TSHR | |
| SCHEMBL8644251 | 0.67 | LTA4H (0.42) | KDM4EALDH1A1CYP2D6 | |
| SCHEMBL16474300 | 0.67 | OPRM1 (0.44) | OPRM1KDM4EOPRD1OPRK1CYP2D6 | |
| SCHEMBL20270422 | 0.67 | LTA4H (0.43) | DRD2OPRM1ALDH1A1TDP1TSHR | |
| SCHEMBL28317515 | 0.66 | OPRM1 (0.43) | OPRM1OPRD1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | DRD2 3252/4885OPRM1 4101/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.